Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors

被引:0
作者
Mahmoud A. Al-Sha’er
Mutasem O. Taha
机构
[1] Zarqa University,Faculty of Pharmacy
[2] University of Jordan,Drug Discovery Unit, Department of Pharmaceutical Sciences, Faculty of Pharmacy
来源
Journal of Molecular Modeling | 2012年 / 18卷
关键词
Docking; LigandFit; dbCICA; Heat shock protein 90α; Anticancer;
D O I
暂无
中图分类号
学科分类号
摘要
Heat shock protein (Hsp90α) has been recently implicated in cancer, prompting several attempts to discover and optimize new Hsp90α inhibitors. Towards this end, we docked 83 diverse Hsp90α inhibitors into the ATP-binding site of this chaperone using several docking–scoring settings. Subsequently, we applied our newly developed computational tool—docking-based comparative intramolecular contacts analysis (dbCICA)—to assess the different docking conditions and select the best settings. dbCICA is based on the number and quality of contacts between docked ligands and amino acid residues within the binding pocket. It assesses a particular docking configuration based on its ability to align a set of ligands within a corresponding binding pocket in such a way that potent ligands come into contact with binding site spots distinct from those approached by low-affinity ligands, and vice versa. The optimal dbCICA models were translated into valid pharmacophore models that were used as 3D search queries to mine the National Cancer Institute’s structural database for new inhibitors of Hsp90α that could potentially be used as anticancer agents. The process culminated in 15 micromolar Hsp90α ATPase inhibitors.
引用
收藏
页码:4843 / 4863
页数:20
相关论文
共 339 条
[1]  
Mahalingam D(2009)Targeting HSP90α for cancer therapy Br J Cancer 100 1523-1529
[2]  
Swords R(2006)Emerging Hsp90α inhibitors: from discovery to clinic Anti Cancer Agents Med Chem 6 1-8
[3]  
Carew JS(2004)Inhibitors of Hsp90α and other chaperones for the treatment of cancer Expert Opin Ther Pat 14 837-847
[4]  
Nawrocki ST(2003)Heat shock protein 90 as a molecular target for cancer therapeutics Cancer Cell 3 213-217
[5]  
Bhalla K(2008)The Hsp90α molecular chaperone: an open and shut case for treatment Biochem J 41 439-453
[6]  
Giles FJ(1999)Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity Invest New Drugs 17 361-373
[7]  
Chiosis G(2003)Development of radicicol analogues Curr Cancer Drug Targets 3 359-369
[8]  
Rodina A(2008)Discovery and development of purine scaffold Hsp90α inhibitors Expert Opin Drug Discov 3 99-114
[9]  
Moulick K(2007)A novel class of Hsp90α inhibitors isolated by structure-based virtual screening Bioorg Med Chem Lett 17 6345-6349
[10]  
Dymock BW(2006)4-Amino derivatives of the Hsp90α inhibitor CCT018159 Bioorg Med Chem Lett 16 2543-2548